Database

Startups

Main Industry
Health Care
Main Product/Service
1. CVM-1118 (Foslinanib)
2. Zelnite®
3. TRX-NOC
4. TRX-920
5. TRX-105
Founded Year
2011
Unified Business No.
53529570
Status
Active
Number of Employees
0
Total Paid-in Capital
1,119,899,080 (NT$)
Location of Company
Taiwan , Taipei City
Exit Status
Emerging Stock Exchange(2017)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
TaiRx is an efficient Pharma Management Corporate to develop a new generation of oncology molecule.TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, TaiRx also extended our reach to the therapy of other m



More ↓

Similar Companies

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

XANTHO BIOTECHNOLOGY CO., LTD.

*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age g